Clonal selection and double-hit events involving tumor suppressor genes underlie relapse in myeloma-Reference-Cited by-同舟云学术

Clonal selection and double-hit events involving tumor suppressor genes underlie relapse in myeloma

Published:2016-09-29 Issue:13 Volume:128 Page:1735-1744
ISSN:0006-4971
Container-title:Blood
language:en
Short-container-title:

Author:

Weinhold Niels¹,Ashby Cody¹,Rasche Leo¹,Chavan Shweta S.¹,Stein Caleb¹,Stephens Owen W.¹,Tytarenko Ruslana¹,Bauer Michael A.¹,Meissner Tobias²,Deshpande Shayu¹,Patel Purvi H.¹,Buzder Timea¹,Molnar Gabor¹,Peterson Erich A.¹,van Rhee Frits¹,Zangari Maurizio¹,Thanendrarajan Sharmilan¹,Schinke Carolina¹,Tian Erming¹,Epstein Joshua¹,Barlogie Bart¹,Davies Faith E.¹,Heuck Christoph J.¹,Walker Brian A¹,Morgan Gareth J.¹

Affiliation:

1. Myeloma Institute, University of Arkansas for Medical Sciences, Little Rock, AR; and

2. Department of Molecular and Experimental Medicine, Avera Cancer Institute, La Jolla, CA

Abstract

Key PointsHits in driver genes and bi-allelic events affecting tumor suppressors increase apoptosis resistance and proliferation rate–driving relapse. Excessive biallelic inactivation of tumor suppressors in high-risk cases highlights the need for TP53-independent therapeutic approaches.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Link

http://ashpublications.org/blood/article-pdf/128/13/1735/1395654/1735.pdf

Reference34 articles.

1. Multiple myeloma.;Röllig;Lancet,2015

2. Curing myeloma at last: defining criteria and providing the evidence.;Barlogie;Blood,2014

3. Intraclonal heterogeneity is a critical early event in the development of myeloma and precedes the development of clinical symptoms.;Walker;Leukemia,2014

4. Clonal competition with alternating dominance in multiple myeloma.;Keats;Blood,2012

5. Heterogeneity of genomic evolution and mutational profiles in multiple myeloma.;Bolli;Nat Commun,2014

Cited by 172 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Temporal Genomic Dynamics Shape Clinical Trajectory in Multiple Myeloma;2024-09-04

2. Multi-omic and functional screening reveal targetable vulnerabilities inTP53mutated multiple myeloma;2024-08-23

3. Genomic and immune determinants of resistance to daratumumab-based therapy in relapsed refractory multiple myeloma;Blood Cancer Journal;2024-07-19

4. RECENT ADVANCES IN THE DEFINITION OF THE MOLECULAR ALTERATIONS OCCURRING IN MULTIPLE MYELOMA;Mediterranean Journal of Hematology and Infectious Diseases;2024-06-29

5. Retrospective study on pomalidomide‐PACE as a salvage regimen in aggressive relapsed and refractory multiple myeloma;European Journal of Haematology;2024-06-19